ResMed Inc (RMD)
Return on equity (ROE)
| Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 1,020,950 | 897,556 | 779,437 | 474,505 | 621,674 |
| Total stockholders’ equity | US$ in thousands | 4,864,040 | 4,129,900 | 3,360,750 | 2,885,680 | 2,497,030 |
| ROE | 20.99% | 21.73% | 23.19% | 16.44% | 24.90% |
June 30, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $1,020,950K ÷ $4,864,040K
= 20.99%
ResMed Inc's return on equity (ROE) has shown a fluctuating trend over the past five years. The ROE decreased from 24.90% in 2020 to 16.44% in 2021, indicating a decline in the company's ability to generate profits from its shareholders' equity. However, there was a subsequent increase in ROE to 23.19% in 2022, suggesting improved profitability performance.
In the most recent year, ending June 30, 2024, ResMed Inc's ROE was 20.99%, which is slightly lower than the previous year's figure. This indicates that the company's profitability in relation to shareholders' equity has decreased slightly.
Overall, ResMed Inc's ROE has demonstrated some volatility, with fluctuations in profitability performance over the five-year period. It is important for investors to monitor these trends closely to assess the company's ability to generate returns on its equity investments.
Peer comparison
Jun 30, 2024